Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer.

Fiche publication

Date publication

juin 2021

Journal

Journal for immunotherapy of cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ARNOULD Laurent , Pr GHIRINGHELLI François , Dr LADOIRE Sylvain , Mme TRUNTZER Caroline , Dr LIMAGNE Emeric , Dr DERANGERE Valentin , Dr THIBAUDIN Marion

Tous les auteurs :
Klopfenstein Q, Derangère V, Arnould L, Thibaudin M, Limagne E, Ghiringhelli F, Truntzer C, Ladoire S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34083415

Résumé

The prognosis of early breast cancer is linked to clinic-pathological stage and the molecular characteristics of intrinsic tumor cells. In some patients, the amount and quality of tumor-infiltrating immune cells appear to affect long term outcome. We aimed to propose a new tool to estimate immune infiltrate, and link these factors to patient prognosis according to breast cancer molecular subtypes.